摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(9ci)-2,3-二氢-2-氧代-1H-苯并咪唑-4-羧酸 | 291289-41-3

中文名称
(9ci)-2,3-二氢-2-氧代-1H-苯并咪唑-4-羧酸
中文别名
2-氧代-2,3-二氢-1H-苯并[d]咪唑-4-羧酸
英文名称
2-oxo-2,3-dihydro-1H-benzo[d]imidazole-4-carboxylic acid
英文别名
2-oxo-2,3-dihydro-1H-benzimidazole-4-carboxylic acid;2-Oxo-2,3-dihydro-1H-benzimidazol-4-carbonsaeure;2-oxo-1,3-dihydrobenzimidazole-4-carboxylic acid
(9ci)-2,3-二氢-2-氧代-1H-苯并咪唑-4-羧酸化学式
CAS
291289-41-3
化学式
C8H6N2O3
mdl
MFCD18074080
分子量
178.147
InChiKey
NEGPAVSXSLHMAR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    243.5±19.0 °C(Predicted)
  • 密度:
    1.489±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.1
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    78.4
  • 氢给体数:
    3
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2933990090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:002aa7ac8bee646d9b196446aebbfb82
查看

制备方法与用途

2-氧代-2,3-二氢-1H-苯并[d]咪唑-4-羧酸用于有机合成。

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
    申请人:Merck & Co., Inc.
    公开号:US06303593B1
    公开(公告)日:2001-10-16
    The present invention is directed to pyrrolidine compounds of the formula I: (wherein R1, R2, R3, R4c, R4d, and R4f are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-3 and/or CCR-5.
    本发明涉及式I的吡咯烷化合物(其中R1、R2、R3、R4c、R4d和R4f在此处定义),这些化合物可用作趋化因子受体活性的调节剂。具体而言,这些化合物可用作趋化因子受体CCR-3和/或CCR-5的调节剂。
  • [EN] ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS<br/>[FR] DÉRIVÉS D'ARYLAMIDE EN TANT QU'AGENTS BLOQUANTS DE TTX-S
    申请人:RAQUALIA PHARMA INC
    公开号:WO2012053186A1
    公开(公告)日:2012-04-26
    The present invention relates to arylamide derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.
    本发明涉及具有对电压门控钠通道(如TTX-S通道)具有阻塞活性的芳基酰胺衍生物,用于治疗或预防涉及电压门控钠通道的疾病和疾病。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗涉及电压门控钠通道的这类疾病中使用这些化合物和组合物。
  • Rational design, synthesis, and structure–activity relationship of benzoxazolones: New potent mglu5 receptor antagonists based on the fenobam structure
    作者:Simona M. Ceccarelli、Georg Jaeschke、Bernd Buettelmann、Jörg Huwyler、Sabine Kolczewski、Jens-Uwe Peters、Eric Prinssen、Richard Porter、Will Spooren、Eric Vieira
    DOI:10.1016/j.bmcl.2006.12.006
    日期:2007.3
    A novel class of potent and stable mGlu5 receptor antagonists was developed by combining information from a high-throughput screening campaign with the structure of the known anxiolytic fenobam. Representative compounds from this class show favorable pharmacokinetic properties and are active in an in vivo model of anxiety.
    通过将来自高通量筛选活动的信息与已知的抗焦虑性芬巴胺的结构相结合,开发出了一类新型的有效且稳定的mGlu5受体拮抗剂。该类别的代表性化合物表现出有利的药代动力学性质,并且在体内焦虑模型中具有活性。
  • [EN] PIPERIDINE-2, 6-DIONE DERIVATIVES WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF<br/>[FR] DÉRIVÉS DE PIPÉRIDINE-2,6-DIONE QUI SE LIENT AU CÉRÉBLON, ET LEURS PROCÉDÉS D'UTILISATION
    申请人:CAPTOR THERAPEUTICS S A
    公开号:WO2021105334A1
    公开(公告)日:2021-06-03
    The present invention provides novel compounds which bind to cereblon, and methods of use thereof. The compounds are represented by Formulas (I) and (II), below: (I) wherein Rx is selected from (Ia), (Ib), (Ic) and (Id); (II) wherein Ry is selected from (IIa), (IIb), (IIc) and (IId).
    本发明提供了一种与 cereblon 结合的新化合物,以及其使用方法。该化合物由以下的公式 (I) 和 (II) 表示:(I) 中 Rx 选自 (Ia)、(Ib)、(Ic) 和 (Id);(II) 中 Ry 选自 (IIa)、(IIb)、(IIc) 和 (IId)。
  • BENZIMIDAZOLE COMPOUNDS
    申请人:Aso Kazuyoshi
    公开号:US20100056515A1
    公开(公告)日:2010-03-04
    There is provided a compound of the formula (I): wherein R 1 is an optionally substituted C 1-10 alkyl; R 2 is H, or a C 1-6 alkyl which may be substituted with 1 to 3 substituents; R 3 is a 5- or 6-membered aromatic group which may be substituted with 1 to 5 substituents, wherein the 5- or 6-membered aromatic group may be fused with a 5- or 6-membered ring which may be substituted with 1 to 3 C 1-6 alkyls; R 4 is a hydrogen, a halogen, a hydroxy, a cyano, a C 1-6 alkyl or a C 1-6 alkoxy; Z is —O—, —S—, —SO—, —SO 2 —, or —NR 5 — wherein R 5 is a hydrogen or a C 1-6 alkyl; or a salt thereof or a prodrug thereof, which have CRF receptor antagonist activity and use thereof.
    提供了一个式子(I)的化合物: 其中,R1是可选取代的C1-10烷基;R2是氢,或者是一个C1-6烷基,该烷基可以用1至3个取代基取代;R3是一个5-或6-成员芳香基团,可以用1至5个取代基取代,其中5-或6-成员芳香基团可以与一个5-或6-成员环融合,该环可以用1至3个C1-6烷基取代;R4是氢、卤素、羟基、氰基、C1-6烷基或C1-6烷氧基;Z是-O-、-S-、-SO-、-SO2-或-NR5-,其中R5是氢或C1-6烷基;或其盐或前药,具有CRF受体拮抗活性和使用方法。
查看更多